Back to search

Article

A screen for combination therapies in <i>BRAF/NRAS</i> wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination

2017-09-28

Abstract excerpt

Despite recent therapeutic advances in the management of BRAF V600 -mutant melanoma, there is still a compelling need for more effective treatments for patients who developed BRAF / NRAS wild type disease. Since the activity of single targeted agents is limited by innate and acquired resistance, we performed a high-throughput drug screen using 180 drug combinations to generate over 18,000 viability curves, with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a7874f2b-ef64-5be6-ae29-d22a2184fb47
DOI
10.1101/195354
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A screen for combination therapies in <i>BRAF/NRAS</i> wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combinationDOI 10.1101/195354
BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.Semantic proximity
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.Semantic proximity
AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma.Semantic proximity
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by <i>NRAS</i> or <i>MEK</i> MutationsSemantic proximity
Clinical Development of BRAF plus MEK Inhibitor Combinations.Semantic proximity
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.Semantic proximity
Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.Semantic proximity
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling.Semantic proximity
A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.Semantic proximity
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentSemantic proximity
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Semantic proximity
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.Semantic proximity
Select a neighboring publication to make it the new centre.